HOLX Stock Performance, Insider Transaction and News

HOLX - Hologic, Inc.

Market Cap	18.66B	P/E	25.06	EPS this Y	3.00%	Ern Qtrly Grth	-
Income	701.5M	Forward P/E	19.01	EPS next Y	7.10%	50D Avg Chg	-5.00%
Sales	3.99B	PEG	2.56	EPS past 5Y	3.38%	200D Avg Chg	-4.00%
Dividend	N/A	Price/Book	3.58	EPS next 5Y	7.70%	52W High Chg	-14.00%
Recommedations	2.30	Quick Ratio	3.07	Shares Outstanding	232.27M	52W Low Chg	27.00%
Insider Own	0.71%	ROA	6.45%	Shares Float	229.07M	Beta	0.98
Inst Own	100.20%	ROE	13.85%	Shares Shorted/Prior	5.18M/5.17M	Price	75.67
Gross Margin	60.58%	Profit Margin	17.59%	Avg. Volume	1,615,501	Target Price	87.93
Oper. Margin	26.09%	Earnings Date	Nov 7	Volume	2,308,192	Change	-1.23%

Healthcare | Medical Instruments & Supplies | United States

About Hologic, Inc.

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Hologic, Inc. News

11/19/24	Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
11/15/24	Should You Retain Hologic Stock in Your Portfolio Now?
11/14/24	Hologic to Webcast Presentations at Upcoming Investor Conferences
11/08/24	Implied Volatility Surging for Hologic (HOLX) Stock Options
11/08/24	Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
11/08/24	Hologic Post Q4 Earnings Miss: Time to Buy, Hold or Sell the Stock?
11/05/24	Hologic Q4 Earnings Lag, Revenues Top, Stock Down in Aftermarket
11/05/24	Q4 2024 Hologic Inc Earnings Call
11/05/24	Hologic Inc (HOLX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Challenges
11/04/24	Hologic (HOLX) Reports Q4 Earnings: What Key Metrics Have to Say
11/04/24	Hologic (HOLX) Q4 Earnings Miss Estimates
11/04/24	Hologic: Fiscal Q4 Earnings Snapshot
11/04/24	Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024
10/30/24	Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
10/30/24	Unlocking Q4 Potential of Hologic (HOLX): Exploring Wall Street Estimates for Key Metrics
10/28/24	Hologic (HOLX) Stock Falls Amid Market Uptick: What Investors Need to Know
10/28/24	Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
10/28/24	FDA advises clinicians to stop using Hologic radiographic markers
10/25/24	Hologic Recalls Soft Tissue Marker Device BioZorb, FDA Issues Warning After Almost 400 Complaints
10/25/24	Will Non-COVID-19 Diagnostics Sales Drive Hologic's Q4 Earnings?

HOLX Chatroom

NVDAMillionaire Posted - 2 weeks ago

$HOLX Hologic (HOLX): A Steadfast Champion of Women’s Health https://beyondspx.com/article/hologic-holx-a-steadfast-champion-of-women-s-health

Estimize Posted - 2 weeks ago

$HOLX reported 1.01 EPS and 987.90 revenue for Q4. http://www.estimize.com/intro/holx?chart=historical&metric_name=eps&utm_content=HOLX&utm

Thestocktraderhubzee Posted - 2 weeks ago

$HOLX UBS Maintains Neutral on Hologic, Raises Price Target to $90

IN0V8 Posted - 2 weeks ago

$HOLX Opportunity RBC raises target price to $89 from $86

DonCorleone77 Posted - 2 weeks ago

$HOLX Hologic sees FY25 EPS $4.25-$4.35, consensus $4.32 Sees FY25 revenue $4.15B-$4.20B, consensus $4.21B

DonCorleone77 Posted - 2 weeks ago

$HOLX Hologic sees Q1 EPS $1.00-$1.03, consensus $1.03 Sees Q1 revenue $1.025B-$1.035B, consensus $1.04B

Wigglyick Posted - 2 weeks ago

Eyes on $PLTR $HOLX $BWXT …….. ERs after close today.

Doozio Posted - 3 weeks ago

$HOLX wen a 🧠👀 becomes da FUTUre of 🧠⏰ during 🧠⏰♾️😇📦

DheepsTrades324 Posted - 3 weeks ago

$HOLX pretty crazy setup here going into earnings Monday…

Wigglyick Posted - 3 weeks ago

$HOLX Optimism going into ER on Monday , 11/04

swingingtech Posted - 10/28/24

$HOLX https://wallstreetwaves.com/insight-into-hologics-upcoming-quarterly-earnings-key-takeaways/

DonCorleone77 Posted - 10/25/24

$HOLX FDA says 'do not use' Hologic BioZorb Markers In an updated safety communication dated October 25, the FDA states: "The U.S. Food and Drug Administration is alerting consumers, health care providers and health care facilities not to use BioZorb Markers and BioZorb LP Markers by Hologic Inc. On October 25, 2024, Hologic announcedExternal Link Disclaimer a voluntary recall for removal of all lots of unused BioZorb Markers. The recall is due to reports of serious adverse events occurring in patients who had the devices implanted in breast tissue. The FDA is issuing this communication to help ensure you are aware of the manufacturer's most recent recall notice and the recommended actions."

WeeklyTrader Posted - 1 month ago

The future is bright for $HOLX! RSI: 56.01% 50-day MA: $81.07 200-day MA: $76.62

erevnon Posted - 1 month ago

Needham reiterates Hologic $HOLX at Buy and maintains a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

briefingcom Posted - 1 month ago

$HOLX: Hologic to acquire Gynesonics, a privately held medical device company, for approximately $350 mln https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241014081017HOLX&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

SparkySC Posted - 1 month ago

$HOLO $SPY $HOLX $TSLA Good or Bad?

SparkySC Posted - 1 month ago

$HOLO a better play ? $HOLX $WIMI

erevnon Posted - 1 month ago

Mizuho maintains Hologic $HOLX at Outperform and raises the price target from $85 to https://marketsblock.com/stock-upgrades-and-downgrades/

erevnon Posted - 1 month ago

Citigroup downgrades Hologic $HOLX from Buy to Neutral and lowers the price target from $95 to https://marketsblock.com/stock-upgrades-and-downgrades/

Shlobby Posted - 2 months ago

$HOLX this trade about to go. All MAs are lined up and ready.

Thelonius_Stonk Posted - 2 months ago

$HOLX monster base. adding to watchlist. thanks @DonCorleone77 and @contangoz for putting on my radar

DonCorleone77 Posted - 2 months ago

$HOLX Hologic announces $1.5B share repurchase program In a regulatory filing, Hologic disclosed that, on September 12, the Board of Directors of Hologic authorized a new stock repurchase program, with a five-year term, to repurchase up to $1.5B of the company's outstanding common stock. This new stock repurchase authorization is in addition to the company's prior stock repurchase authorization, which has approximately $190M remaining as of September 12, 2024.